Calliditas Therapeutics AB (publ) (CLTEF) Comparison with companies in other sectors?

Calliditas Therapeutics AB (publ) has a share price of 53.67M. You can analyze Calliditas Therapeutics AB (publ) (CLTEF) competitors across different market sectors through stock heatmaps.

What are CLTEF's NET and operating margins?

Calliditas Therapeutics AB (publ) (CLTEF) operating margin is around -0.50, and net profit margin is approximately -0.51 as of the latest reports.

In what way does CLTEF's earnings per share (EPS) trend reflect its financial momentum?

Calliditas Therapeutics AB (publ) (CLTEF) EPS is -1.07 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Calliditas Therapeutics AB (publ) is -5.42, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Calliditas Therapeutics AB (publ)?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Calliditas Therapeutics AB (publ) like P/E which is -74.03, P/B which is 39.83, and PEG which is -0.08. Compare them with sector averages to evaluate if the stock is priced fairly.

Calliditas Therapeutics AB (publ)

CLTEF•PNK

Healthcare

Biotechnology

$5.80

$-0.01(-0.17%)

Fundamental Analysis of Calliditas Therapeutics AB (publ) (CLTEF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-1.07

P/E Ratio

-5.42

ROE

-0.43%

Net Margin

-0.51%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$387.73M

Shares OutstandingTotal number of shares issued

$53.67M

Book Value/ShareNet worth per share

$1.39

Revenue/ShareAnnual revenue per share

$1.45

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-1.07

Net MarginNet income as percentage of revenue

-51.35%

Operating MarginOperating income as percentage of revenue

-49.68%

ROEReturn on shareholders' equity

-42.74%

ROAReturn on total assets

-21.11%

ROCEReturn on capital employed

-24.50%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.57

Cash/ShareCash and equivalents per share

$2.26

FCF YieldFree cash flow as percentage of market cap

-0.82%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for CLTEFFinancial Ratios Analysis details for CLTEF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CLTEFSector Benchmarking details for CLTEF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Calliditas Therapeutics AB (publ) Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Calliditas Therapeutics AB (publ). Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Calliditas Therapeutics AB (publ)'s unique business strengths and challenges.

Key Financial Metrics for Calliditas Therapeutics AB (publ)

For Calliditas Therapeutics AB (publ), essential financial indicators include EPS -1.07, PE -5.42, and ROE -0.43. These key ratios reveal insights into Calliditas Therapeutics AB (publ)'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Calliditas Therapeutics AB (publ) with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Calliditas Therapeutics AB (publ)

Metrics like Net Margin -51.35% and ROA -21.11% shed light on how well Calliditas Therapeutics AB (publ) is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Calliditas Therapeutics AB (publ) can sustain its operations and continue growing in the future.

Valuation and Market Position of Calliditas Therapeutics AB (publ)

Using ratios such as P/B Ratio 39.83 and PEG Ratio -0.08, investors can assess whether Calliditas Therapeutics AB (publ) is appropriately valued based on its financials and growth potential. These figures, combined with Calliditas Therapeutics AB (publ)'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Calliditas Therapeutics AB (publ)

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $-0.57, provide a snapshot of Calliditas Therapeutics AB (publ)'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Calliditas Therapeutics AB (publ), is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Calliditas Therapeutics AB (publ)

Investing in Calliditas Therapeutics AB (publ) based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Calliditas Therapeutics AB (publ) focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;